Cargando…

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Manfredi, Battista Rini, Giovam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258692/
https://www.ncbi.nlm.nih.gov/pubmed/22291726
http://dx.doi.org/10.5114/aoms.2011.20597